Business
DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus’ INTERCEPT™ Blood System in Routine Clinical Practice
CONCORD, Calif., January 22, 2026--Cerus Corporation (Nasdaq: CERS) today announced the start of the INITIATE study by the German Red Cross Blood Donation Service Baden-Württemberg – Hessen and its subsidiary organization, the German Red Cross Blood Donation Service North-East. The prospective, multicenter, non-interventional safety study, sponsored by DRK Blood Donation Service Baden-Württemberg-Hessen, is the first of its kind in Germany to evaluate the routine use of pathogen-inactivated plat
About this update from Cerus Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/6bbea32a8383c12e1665bbeef390d7c7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SuyHpJSRPowzQvT_RFhTnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6bbea32a8383c12e1665bbeef390d7c7","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/4J9nC.OmuhRqf6ckWaWc5g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/6bbea32a8383c12e1665bbeef390d7c7","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CONCORD, Calif., January 22, 2026--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the start of the INITIATE study by the German Red Cross Blood Donation Service Baden-Württemberg – Hessen and its subsidiary organization, the German Red Cross Blood Donation Service North-East. The prospective, multicenter, non-interventional safety study, sponsored by DRK Blood Donation Service Baden-Württemberg-Hessen, is the first of its kind in Germany to evaluate the routine use of pathogen-inactivated platelet concentrates utilizing the INTERCEPT Blood System in a clinical setting.","length":594,"tagName":"p"},{"type":"text","content":"Platelet concentrates (PC) are an important part of the blood supply in Germany. They are needed for patients with low platelet count or impaired platelet function, particularly in conditions such as leukemia, severe bleeding, after stem cell transplantation or chemotherapy, or during major surgical procedures. Pathogen Inactivation (PI) is intended to further reduce the risk of transmission of bacteria, viruses or other transfusion-associated infections.","length":459,"tagName":"p"},{"type":"text","content":"The INITIATE study is currently being conducted in selected hospitals in several regions served by the DRK Blood Donation Services Baden-Württemberg – Hessen and North-East. The aim of the non-interventional study is to gain comprehensive insights into the integration and routine suitability of supplying pathogen-inactivated platelet concentrates to patients in Germany and to further evaluate the safety profile of platelet concentrates treated with Cerus’ I...